Kidney cancer: Toxicity management, symptom control, and palliative care

Victoria Sinibaldi, Caroline F. Pratz, Olga Yankulina

Research output: Contribution to journalReview article

Abstract

The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Clinical Oncology
Volume36
Issue number36
DOIs
StatePublished - Dec 20 2018

Fingerprint

Kidney Neoplasms
Palliative Care
Immunotherapy
Nursing Societies
Oncology Nursing
Documentation
Neoplasms
Quality of Life
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kidney cancer : Toxicity management, symptom control, and palliative care. / Sinibaldi, Victoria; Pratz, Caroline F.; Yankulina, Olga.

In: Journal of Clinical Oncology, Vol. 36, No. 36, 20.12.2018, p. 1-7.

Research output: Contribution to journalReview article

Sinibaldi, Victoria ; Pratz, Caroline F. ; Yankulina, Olga. / Kidney cancer : Toxicity management, symptom control, and palliative care. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 36. pp. 1-7.
@article{da06c50f06b54a8abc3af4bcef0b35b3,
title = "Kidney cancer: Toxicity management, symptom control, and palliative care",
abstract = "The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.",
author = "Victoria Sinibaldi and Pratz, {Caroline F.} and Olga Yankulina",
year = "2018",
month = "12",
day = "20",
doi = "10.1200/JCO.2018.79.0188",
language = "English (US)",
volume = "36",
pages = "1--7",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Kidney cancer

T2 - Toxicity management, symptom control, and palliative care

AU - Sinibaldi, Victoria

AU - Pratz, Caroline F.

AU - Yankulina, Olga

PY - 2018/12/20

Y1 - 2018/12/20

N2 - The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.

AB - The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.

UR - http://www.scopus.com/inward/record.url?scp=85058560588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058560588&partnerID=8YFLogxK

U2 - 10.1200/JCO.2018.79.0188

DO - 10.1200/JCO.2018.79.0188

M3 - Review article

C2 - 30372391

AN - SCOPUS:85058560588

VL - 36

SP - 1

EP - 7

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -